Aims To investigate the kinetics of the (+)RS-and (−)SR-enantiomers and the carboxylic acid metabolite (MMQ) of the antimalarial drug mefloquine (MQ) in healthy volunteers. Methods Ten subjects of which three were poor metabolizers of debrisoquine received racemic MQ 250 mg once weekly for 16 weeks. The kinetics were followed in plasma and urine and evaluated by individual kinetic modelling as well as by a nonparametric population kinetic method. Results A two-compartment model adequately described the disposition of (+)RS-MQ. CL/F was 6.5±1.8 l h The aims of the present study were to investigate the treatment of multi-drug resistant P. falciparum malaria. The available preparation is a racemate of the (+)RS-MQ and enantioselective kinetics of MQ during long-term prophylaxis including the early phase after drug intake, the renal (−)SR-MQ enantiomers. Both enantiomers are active against P. falciparum in vitro [1] although a slightly higher excretion of the enantiomers and to define any difference between poor and extensive metabolizers of debrisoquine in activity for (+)RS-MQ has been reported [2]. A major problem with MQ is the occurrence of neuropsychiatric the elimination of the MQ enantiomers. For determination of the typical kinetic characteristics for (+)RS-MQ and adverse reactions, in particular after therapeutic doses [3]. It has not been clarified whether the potential to cause adverse (−)SR-MQ in this population, we performed a population analysis using the nonparametric NPEM method [8]. reactions differs between the enantiomers. MQ is a local irritant that cannot be given intravenously. Hence, absoluteCompared with the standard two-stage method, more accurate estimates of the distribution of kinetic parameters bioavailability and systemic clearance are not known. The metabolism of MQ is not well characterised. At steady-state, in a population can be obtained with the population methodology as it takes into account the quality of the data an average of 9% of the dose is excreted unchanged in urine and 4% as the carboxylic acid metabolite (MMQ) [4]. MMQ from each subject and the covariance between the parameters. is regarded as the main metabolite in man but it has no significant antimalarial effect in vitro [5]. Methods A recent pharmacokinetic study during prophylactic intake of MQ (250 mg once weekly) demonstrated a Subjects significantly longer mean half-life of (−)SR-MQ compared Ten healthy adult Caucasian volunteers (mean age 42 years, range 29-50 years, six females and four males) participated

A 7% increase on the previous year was observed in 2004, with 192 cases - the highest number of annual notifications since the mid-1980s

A female assistant at a nursery in a wealthy suburb of Stockholm was diagnosed with smear positive advanced pulmonary tuberculosis in August 2005.

No abstract